ArticleParasites & vectors2025
Evaluation of four chimeric Trypanosoma cruzi recombinant antigens for serological diagnosis of chronic Chagas disease in dogs: a phase II study.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Double-antigen sandwich ELISA based on chimeric antigens for detection of antibodies to Trypanosoma cruzi in human sera - A phase II study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundDogs are recognized as epidemiologically significant reservoirs for Trypanosoma cruzi, the causative agent of Chagas disease (CD), owing to their close association with humans and their role in sustaining the domestic and peridomestic transmission cycle. Canine seropositivity often correlates with human CD prevalence. However, the lack of commercial, high-performance diagnostic assays for canine infections remains a significant barrier to effective surveillance. Previously, our group demonstrated the diagnostic potential of four chimeric T. cruzi antigens in a phase I study, yielding results comparable to those observed in humans. The present phase II study expands upon these findings by evaluating these antigens in a larger canine cohort using indirect enzyme-linked immunosorbent assay (ELISA). The objective of this study was to assess the diagnostic performance of four chimeric recombinant T. cruzi antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) in immunoassays for the detection of anti-T. cruzi IgG in dogs with chronic Chagas disease.
methodsImmunoassays were optimized by checkerboard titration. In this phase II study, the diagnostic performance of the IBMP antigens was evaluated using 1260 canine serum samples. Cross-reactivity was assessed in an additional 752 samples from dogs with unrelated infectious diseases. The performance of the chimeric antigens was compared with a commercial human-adapted assay (Gold ELISA Chagas).
resultsThe Instituto de Biologia Molecular do Paraná (IBMP) antigens demonstrated area under the curve (AUC) values ranging from 89.0% to 97.4%, with diagnostic accuracy between 87.4% and 96%. IBMP-8.2 exhibited the highest sensitivity (90.3%), while IBMP-8.1, IBMP-8.3, and IBMP-8.4 achieved sensitivities of 74.8%, 72.6%, and 79.6%, respectively. The highest specificity was observed for IBMP-8.4 (99.6%), followed by IBMP-8.3 (99.0%), IBMP-8.2 (96.5%), and IBMP-8.1 (90.6%). The Gold ELISA Chagas assay showed a sensitivity of 62.3%, specificity of 98.6%, and accuracy of 89.9%. IBMP-8.2 exhibited the lowest cross-reactivity index (0.9%), closely approximating an ideal diagnostic assay.
conclusionsThe IBMP chimeric antigens demonstrated strong diagnostic performance for detecting T. cruzi infection in dogs, significantly enhancing immunoassay accuracy and minimizing diagnostic failures due to cross-reactivity. The combined use of these antigens represents a promising strategy to further improve sensitivity and specificity in future diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.